BF Biosciences Limited reported a strong financial performance for the nine months ended 31 March 2026
Filed as: Financial Results for the Quarter Ended 31-03-2026
Summary
BF Biosciences Limited reported a strong financial performance for the nine months ended 31 March 2026, with revenue reaching Rs 7.24 billion and net profit at Rs 465 million, reflecting significant growth over the prior period.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Revenue | PKR 7.24 billion | PKR 4.21 billion | +71.8% |
| Net Profit | PKR 465 million | PKR 320 million | +45.1% |
| Earnings Per Share | PKR 5.26 | PKR 4.08 | +28.9% |
| Gross Profit | PKR 3.19 billion | PKR 1.74 billion | +83.6% |
| Cash and Cash Equivalents | PKR 72 million | PKR 268 million | -73.1% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Revenue increased by 71.75% to Rs 7.24 billion, up from Rs 4.21 billion in the prior period.
- Net profit rose by 45.12% to Rs 465 million compared to Rs 320 million in the previous period.
- Earnings per share improved to Rs 5.26 from Rs 4.08, indicating enhanced profitability.
BF Biosciences Limited (BFBIO) on Nafa
Last price Rs 135.48 · Pharmaceuticals · You can own BFBIO shares from your phone.
More BFBIO announcements
- NoticeTransmission of Quarterly Financial Statements for the Period Ended 30-09-2026
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeAnnual Progress Report for the Year Ended June 30, 2026
- Financial resultBF Biosciences Limited reported a net profit of Rs 184.88 million for the first quarter ended 30 September 2026Filed as: Financial Results for the Quarter Ended 30-09-2026
- NoticeBoard Meeting
- NoticeTransmission of Annual Financial Statements for the Year Ended 30-06-2026
Source: BF Biosciences Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.